Compare Badger Meter Inc (BMI) vs Summit Therapeutics Inc (SMMT) Price & Performance

Badger Meter (BMI) trades at $132.67, down 2.76% on the day, with a bearish technical signal and mixed earnings history. Key fundamentals include a P/E of 31.78, net income margin of 14.27%, and ROE of 18.48%. Recent news highlights insider buying and multiple class-action lawsuits, while cash flow trends show net outflows.

The outlook is cautious due to legal risks and earnings misses, but analyst consensus targets $155.20, implying upside. Risks include litigation and competitive pressures, while institutional interest and solid profitability offer some support.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.